Maybe—but only if larger, longer-term studies replicate the findings from a randomized trial of 144 patients (mean age = 66 years) published recently in the Annals of the Rheumatic Diseases.

Subjects with knee osteoarthritis (OA) in the double-blind Annals study received either placebo or up to 25 mg per week of oral methotrexate over a 28-week period. At 28 weeks, researchers found greater reductions in knee pain and larger improvements in scores of physical function and activities of daily living in the methotrexate group than in the placebo group. The authors also noted a significantly greater reduction in synovitis, measured both clinically and with ultrasound, in the methotrexate group relative to the placebo group.

Visit Original Source

Submit Community Content

If you have orthopedic information that you would like to share with the Orthogate Community, please register/login and submit your news, event, job, article, case or workshop from the Submit Content menu under the My Account area. Learn more!